Lonza recently announced the completion of the expansion of its Highly Potent API (HPAPI) multipurpose suite in Visp (CH). The expansion adds development and manufacturing capacity for Antibody-drug conjugates (ADC) payloads, supporting the entire development and manufacturing pipeline from feasibility studies to commercial supply.
EPM chats with Lonza's Giovanna Libralon, Small Molecules, and Iwan Bertholjotti, Bioconjugates, who share insights on payload-linker manufacturing and the global market trends for ADC-based therapies, along with the production of antibodies that help increase the precision of ADCs.